using olaparib in gbrca1/2 breast cancer
Published 6 years ago • 1.2K plays • Length 5:43Download video MP4
Download video MP3
Similar videos
-
5:34
treating gbrca1/2-mutated hr breast cancer
-
1:10
dr. tripathy on impact of olaparib approval in brca-positive breast cancer
-
2:21
olaparib: predicting response in breast cancer
-
1:15
dr. robson on the toxicity profile of olaparib in breast cancer
-
9:21
dr. litton on activity of talazoparib in advanced brca1/2 breast cancer
-
5:21
chemotherapy in gbrca1/2 metastatic breast cancer
-
3:05
exploring the use of olaparib in advanced breast cancer
-
2:44
olympia: adjuvant olaparib in gbrcam, her2-negative, high-risk, early breast cancer
-
5:31
fda d.i.s.c.o.: olaparib for gbrcam her2-negative metastatic breast cancer
-
2:46
dr. brufsky on the fda approval of olaparib in brca breast cancer
-
5:51
chemotherapy in early-stage gbrca1/2 breast cancer
-
6:18
value of olaparib in brca-mutated advanced ovarian cancer
-
8:41
parp inhibitors for ovarian cancer: use of olaparib
-
1:25
dr. zakashansky on solo2 with maintenance olaparib in relapsed brca1/2 ovarian cancer
-
0:49
dr. tung discusses the role of olaparib in breast cancer
-
1:27
dr. litton on the impact of parp inhibitors in breast cancer
-
5:19
parp inhibitors for brca-associated tnbc
-
6:35
treatment options for patients with brca1/2
-
1:00
olaparib or abemaciclib high-risk brca positive breast cancer?